AviadoBio

Publications and Presentations

Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer’s Disease

Date: Nov 12, 2026

Conference / Journal: Cell 2026

Author(s): Michael MacDonald, DPhil

vMiX: A Modular AAV-Delivered miRNA Platform For Precise, Durable Gene Silencing Across Indications

Date: Nov 12, 2026

Conference / Journal: Cell 2026

Author(s): Romain Joubert, PhD

Preclinical development of AVB-406: An intravenous AAV-miRNA achieving sustained MAPT knockdown for the treatment of Alzheimer’s disease and other tauopathies

Date: Oct 29, 2026

Conference / Journal: ESGCT 2026

Author(s): Deirdre O'Connor

Silencing of MAPT via AVB-406 in human iPSC-derived neurons: A translational framework for neurodegenerative diseases

Date: Oct 29, 2026

Conference / Journal: ESGCT 2026

Presenter: Martina Esposito Soccoio

Author(s): M. Esposito Soccoio, R. Elsayed, M.L. Reilly, L.S. Brebner, A. Abhilash, D. Cox, M. Donnelly, M. MacDonald, M. Sztyler, J. Kenth-Shah, G. Kooner, A. Martorana, P. Boyce, C. Andreassi, A. Bloom, R. Joubert

Evaluation of rationally designed synthetic promoters for expression in neurons and glial cells

Date: Oct 29, 2026

Conference / Journal: ESGCT 2026

Presenter: Daniel Cox

Author(s): D. Cox, T. Waibel, K. Baker, R. Palacios, A. Evripioti, M. Esposito Soccoio, M.L. Reilly, L.S. Brebner, A. Abhilash, A. Bloom, R. Joubert, M. Roberts, G. Kooner

Leveraging the vMiX™ platform to target alpha-synuclein for the treatment of Parkinson’s disease and other synucleinopathies

Date: Oct 28, 2026

Conference / Journal: ESGCT 2026

Presenter: Guillaume Lo

Author(s): G. Lo, D. Dey, L.S. Brebner, R. Elsayed, M. Donnelly, M. MacDonald, A. Martorana, L. Reilly, E. Dellow, D. Ojutalayo, M. Esposito Soccoio, C. Andreassi, Z. Walker, C.E. Shaw, B. Mota, N.A.M. Nafchi, D. O’Connor, C.J. Miranda, A. Bloom, R. Joubert

ASPIRE-FTD in FTD with GRN Mutations Study Update: A Phase 1/2 Study to Evaluate AVB-101

Date: Oct 19, 2026

Conference / Journal: ISFTD 2026

Presenter: Prof. Rik Vandenberghe, KU Leuven

Author(s): G. Di Fede, G. Klodowska, J.C. Masdeu, B. Pascual, M. Ratajczak, J.D. Rohrer, M. Czarnecki, R.R. Darby, A.G. Murley, J.B. Rowe, R. Vandenberghe, M. Zabek, J.B. Elder, W. Gray, V. Levi, H. Bjartmarz, J.Y.C. Chan, Y.-G. Huang, C.M. Powell, D.L. Cooper

Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models

Date: Sep 17, 2026

Conference / Journal: Journal of Proteome Research

Author(s): Blandine Rougemont, Julie Borgel, Zoe Walker, Irene Zubiri, Ronan O’Cualain, Neda Ali Mohammadi Nafchi, Christopher E. Shaw, Ernestas Sirka, John Isaac, Carlos J. Miranda, and Anna Ettorre

ASPIRE-FTD Study Update: A Phase 1/2 Clinical Study to Evaluate AVB-101 in FTD with GRN Mutations

Date: Jul 14, 2026

Conference / Journal: AAIC 2026

Author(s): G. Klodowska, J.C. Masdeu, B. Pascual, M. Ratajczak, M. Czarnecki, R.R. Darby, A.G. Murley, J.D. Rohrer, J.B. Rowe, M. Zabek, J.B. Elder, W. Gray, C.M. Powell, J.Y.C. Chan, Y.-G. Huang, D.L. Cooper

Development and translational validation of AVB-406: an intravenous AAV-miRNA targeting MAPT for the treatment of Alzheimer’s disease

Date: Jul 14, 2026

Conference / Journal: AAIC 2026

Author(s): Romain Joubert, Madeline Louise Reilly, Deirdre O’Connor, Gurdeep Kooner, Leonie Sophie Brebner, Deborah Ojutalayo, Martina Esposito Soccoio, Randa Elsayed, Catia Andreassi, Emily Dellow, Bibiana C Mota, Neda Ali Mohammadi, Andrea Martorana, Michael MacDonald, Peter Boyce, Agnieszka M Ule, Carlos J Miranda, Christopher E Shaw, John Isaac, Alex Bloom

Preclinical Development Of AVB-406: An Intravenous AAV-miRNA Achieving Sustained MAPT Knockdown To Treat Alzheimer’s Disease

Date: Jul 13, 2026

Conference / Journal: AAIC 2026

Author(s): Deirdre M. O’Connor, Emily Dellow, Bibiana C. Mota, Neda A. Mohammadi, Anna Ettorre, Zoe Walker, Amrita Abhilash, Gurdeep Kooner, Megan Donnelly, Andrea Martorana, Magda Sztyler, Jaya Kenth-Shah, Josh H. Yeung, Quwam Akinlawon, Guillaume Lo, Douglass Dey, Daniel Cox, Peter Boyce, Romain Joubert, Chris E. Shaw, Alex Bloom, John Isaac, Carlos J. Miranda

Development and translational validation of AVB-406: An intravenous AAV-delivered miRNA targeting MAPT for the treatment of Alzheimer’s disease

Date: May 14, 2026

Conference / Journal: ASGCT 2026

Author(s): Romain Joubert

No results found.

AviadoBio is relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into life-changing medicines across neurodegenerative diseases.

© AviadoBio Ltd, 2026. All rights reserved.

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

SCIENCE & Innovation

Find out more about our innovative gene therapies

 

Programs

Our pipeline and programs reflect our mission to deliver the future of gene therapy

 

 

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

 

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here